Metvix

Methyl aminolevulinate, the active ingredient in Metvix, is a photosensitizer presented as a 160 mg/g cream for topical use. It is employed in photodynamic therapy to treat actinic keratosis, a precancerous skin lesion, in adult patients with sun‑exposed skin.

GNH USA supplies Metvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for EU‑approved dermatology products. The company ensures batch‑to‑batch consistency and adheres to stringent quality standards, and our distribution network reaches both private and public healthcare facilities across continents.

Metvix is used in topical photodynamic therapy for precancerous skin lesions.

Actinic keratosis: clears lesions and reduces the risk of progression to squamous cell carcinoma.

Common Side Effects: - Pain or burning sensation at the application site - Redness (erythema) and swelling (edema) - Crusting or scaling of treated skin - Itching or mild irritation

Serious or Rare Side Effects: - Severe phototoxic reaction with extensive skin damage - Secondary infection of the treated area - Persistent scarring or pigmentary changes (hyper‑ or hypopigmentation) - Allergic dermatitis or systemic hypersensitivity reaction

Before using Metvix, consider the following precautions: - Application: apply only to the diagnosed lesion and avoid surrounding healthy skin - Light exposure: protect the treated area from strong sunlight or artificial UV sources for the recommended period after illumination - Phototoxicity: use protective clothing and sunscreen on untreated skin - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus - Contraindications: do not use in patients with known porphyria or hypersensitivity to the formulation - Store at room temperature: keep below 25 °C, in the original container, protected from light and moisture

Metvix may interact with other agents that affect photosensitivity or skin healing.

Major Interactions (Avoid): - Systemic photosensitizing drugs (e.g., tetracyclines, fluoroquinolones) that can increase phototoxic risk - Porphyrinogenic agents (e.g., certain anticonvulsants) that may exacerbate skin reactions - Direct exposure to intense UV‑emitting devices during treatment

Moderate Interactions (Monitor Closely): - Topical retinoids or exfoliants that may heighten local irritation - Concurrent use of potent corticosteroids that could reduce the efficacy of photodynamic therapy